- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Dunbar’s experience includes more than 25 years as CEO, director, and senior manager with many private and public bioscience companies. Most recently he worked with investors as CEO to sell Targesome, an early-stage targeted drug delivery start-up. Prior to Targesome, Dunbar was CEO of Epic Therapeutics, a controlled release formulation company sold to Baxter Healthcare in 2002. Dunbar’s additional experience includes board and management positions at Molecular Probes, Amersham and Ares Serono. He is on the business advisory board of Ultreia Capital in Zurich, Switzerland, and is an outside director with Competitive Technologies, Sonus Pharmaceuticals, and the Valley Medical Center Foundation in San Jose, Calif. Dunbar is a graduate of Auburn University with a degree in electrical engineering and an MBA, and serves on the business school’s MBA advisory board.
QDC is a privately held bioscience company addressing markets in life science research, clinical diagnostics, and clinical imaging – markets with aggregate sales of approximately $67 billion. QDC ‘s quantum dot technology greatly improves the visualization of biological events in the research lab, in clinical diagnostics and during surgery.
“It’s not often one has an opportunity to participate in the commercialization of such powerful technology; and, one with the potential to literally change the landscape for the next generation of biodetection reagents and instrumentation,” said Dunbar. “I look forward to working with the team at Quantum Dot Corp. and building value for our current and future shareholders.”
“George brings a tremendous wealth of experience to QDC and will be a great leader in this time of exponential growth,” said Carol Lou, president and chief operating officer of QDC. “We have set high expectations for ourselves, and we see George as the person to get us to those goals.”
About Quantum Dot Corporation
Founded in 1998, Quantum Dot Corporation (QDC) is a privately held bioscience company commercializing proprietary labeling and detection nanoparticle bioprobes for multiple applications throughout life science and medicine. QDC markets and sells Qdot® nanocrystal products worldwide, directly and through distributors. QDC has over 130 patents and patents-pending, a dominant and extensive position covering quantum dot compositions, synthesis methods, and methods of use. QDC is the exclusive licensee, in the field of biological applications, of pioneering intellectual property licensed from the University of California, MIT, Indiana University, and the University of Melbourne.
Andy Watson at email@example.com or call (510) 887-8775, ext 4106.
Carrie Dorsey firstname.lastname@example.org or call 415-977-1925.
Quantum Dot Corporation
Illuminating the path to scientific discovery™
If you have a comment, please
|The latest news from around the world, FREE|
Only the news you want to read!
University Technology Transfer & Patents
Full-service, expert consulting